Table of contents

New targets

• Subversion of the innate immune response by micro-organisms (1 November, 2002)

  B Fernie-King, D J Seilly, A Davies, P J Lachmann
• Is NF-κB a useful therapeutic target in rheumatoid arthritis? (1 November, 2002)

  M Feldmann, E Andreakos, C Smith, J Bondeson, S Yoshimura, S Kiriakidis, C Monaco, C Gasparini, S Sacre, A Lundberg, E Paleolog, N J Horwood, F M Brennan, B M J Foxwell
• Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis (1 November, 2002)

  R Boismenu, Y Chen, K Chou, A El-Sheikh, R Buelow
• Balancing the immune system: Th1 and Th2 (1 November, 2002)

  W van Eden, R van der Zee, P van Kooten, S E Berlo, P M Cobelens, A Kavelaars, C J Heijnen, B Prakken, S Roord, S Albani
• Mesenchymal stem cells. A potential source for skeletal repair (1 November, 2002)

  W E Fibbe
• Role of RANKL and RANK in bone loss and arthritis (1 November, 2002)

  D Holstead Jones, Y-Y Kong, J M Penninger
• Functions of AP1 (Fos/Jun) in bone development (1 November, 2002)

  E F Wagner
• Treatments no longer in development for rheumatoid arthritis (1 November, 2002)

  E Keystone